New targeted molecular therapies for dedifferentiated thyroid cancer

Journal of Oncology

Volumn , Issue , 2010, Pages

  Ferri, Clodoveo ^b   Antonelli, Alessandro ^a   Ferrari, Silvia Martina ^a   Sebastiani, Marco ^b   Colaci, Michele ^b   Ruffilli, Ilaria ^a   Fallahi, Poupak ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; AAL 881; ANGIOGENESIS INHIBITOR; AXITINIB; B RAF KINASE; B RAF KINASE INHIBITOR; CETUXIMAB; IRINOTECAN; MOTESANIB; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; RADIOACTIVE IODINE; RAS PROTEIN; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; VATALANIB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; DEDIFFERENTIATED THYROID CANCER; DRUG TARGETING; GENE MUTATION; HUMAN; MOLECULAR THERAPY; NONHUMAN; ONCOGENE; PREVALENCE; REVIEW; THYROID CANCER; TREATMENT DURATION; TUMOR VOLUME;

EID: 77954609073     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2010/921682     Document Type: Review

References (60)

1. Mazzaferri E. L., Massoll N., Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin Endocrine-Related Cancer 2002 9 4 227 247
2. Schlumberger M. J., Papillary and follicular thyroid carcinoma The New England Journal of Medicine 1998 338 5 297 306
3. Haugen B. R., Management of the patient with progressive radioiodine non-responsive disease Seminars in Surgical Oncology 1999 16 1 34 41
4. Filetti S., Bidart J.-M., Arturi F., Caillou B., Russo D., Schlumberger M., Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism European Journal of Endocrinology 1999 141 5 443 457
5. Braga-Basaria M., Ringel M. D., Clinical review 158: beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer Journal of Clinical Endocrinology and Metabolism 2003 88 5 1947 1960
6. Oler G., Cerutti J. M., High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes Cancer 2009 115 5 972 980
7. Romei C., Ciampi R., Faviana P., BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer Endocrine-Related Cancer 2008 15 2 511 520
8. Riesco-Eizaguirre G., Rodrguez I., De La Vieja A., The BRAFV600E oncogene induces transforming growth factor secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer Cancer Research 2009 69 21 8317 8325
9. Knauf J. A., Ma X., Smith E. P., Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation Cancer Research 2005 65 10 4238 4245
10. Fagin J. A., How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy Journal of Endocrinology 2004 183 2 249 256
11. Krause D. S., Van Etten R. A., Tyrosine kinases as targets for cancer therapy The New England Journal of Medicine 2005 353 2 172 187
12. Ouyang B., Knauf J. A., Smith E. P., Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo Clinical Cancer Research 2006 12 6 1785 1793
13. Solit D. B., Garraway L. A., Pratilas C. A., BRAF mutation predicts sensitivity to MEK inhibition Nature 2006 439 7074 358 362
14. Knauf J. A., Kuroda H., Basu S., Fagin J. A., RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase Oncogene 2003 22 28 4406 4412
15. Bounacer A., McGregor A., Skinner J., Bond J., Poghosyan Z., Wynford-Thomas D., Mutant ras-induced proliferation of human thyroid epithelial cells requires three effector pathways Oncogene 2004 23 47 7839 7845
16. Shinohara M., Yun J. C., Saji M., Ringel M. D., AKT in thyroid tumorigenesis and progression Endocrinology 2007 148 3 942 947
17. Zhu Z., Ciampi R., Nikiforova M. N., Gandhi M., Nikiforov Y. E., Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity Journal of Clinical Endocrinology and Metabolism 2006 91 9 3603 3610
18. Ciampi R., Nikiforov YE RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis Endocrinology 2007 148 3 936 941
19. De Vita Q., Zannini M., Cirafici A. M., Expression of the RET/PTC1 oncogene impairs the activity of TTF-1 and Pax-8 thyroid transcription factors Cell Growth and Differentiation 1998 9 1 97 103
20. Melillo R. M., Castellone M. D., Guarino V., The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells Journal of Clinical Investigation 2005 115 4 1068 1081
21. Mitsutake N., Knauf J. A., Mitsutake S., Mesa C. Jr., Zhang L., Fagin J. A., Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells Cancer Research 2005 65 6 2465 2473
22. Miyagi E., Braga-Basaria M., Hardy E., Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells Molecular Carcinogenesis 2004 41 2 98 107
23. Jung H. S., Kim D. W., Jo Y. S., Regulation of protein kinase B tyrosine phosphorylation by thyroid-specific oncogenic RET/PTC kinases Molecular Endocrinology 2005 19 11 2748 2759
24. Mitsiades C. S., Negri J., McMullan C., Targeting BRAFV600E in thyroid carcinoma: therapeutic implications Molecular Cancer Therapeutics 2007 6 3 1070 1078
25. Leboeuf R., Baumgartner J. E., Benezra M., BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines Journal of Clinical Endocrinology and Metabolism 2008 93 6 2194 2201
26. Bunone G., Vigneri P., Mariani L., Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features American Journal of Pathology 1999 155 6 1967 1976
27. Lennard C. M., Patel A., Wilson J., Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer Surgery 2001 129 5 552 558
28. de la Torre N. G., Buley I., Wass J. A. H., Turner H. E., Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour Endocrine-Related Cancer 2006 13 3 931 944
29. Schoenberger J., Grimm D., Kossmehl P., Infanger M., Kurth E., Eilles C., Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study Endocrinology 2004 145 3 1031 1038
30. Younes M. N., Yazici Y. D., Kim S., Jasser S. A., El-Naggar A. K., Myers J. N., Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer Clinical Cancer Research 2006 12 11 I 3425 3434
31. Ferrara N., Kerbel R. S., Angiogenesis as a therapeutic target Nature 2005 438 7070 967 974
32. Kerbel R. S., Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006 312 5777 1171 1175
33. Kim D. W., Jo Y. S., Jung H. S., An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases Journal of Clinical Endocrinology and Metabolism 2006 91 10 4070 4076
34. Cheung C. C., Ezzat S., Freeman J. L., Rosen I. B., Asa S. L., Immunohistochemical diagnosis of papillary thyroid carcinoma Modern Pathology 2001 14 4 338 342
35. Hoffmann S., Burchert A., Wunderlich A., Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines Endocrine 2007 31 2 105 113
36. Carlomagno F., Vitagliano D., Guida T., ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases Cancer Research 2002 62 24 7284 7290
37. Mitchell J. C., Parangi S., Angiogenesis in benign and malignant thyroid disease Thyroid 2005 15 6 494 510
38. Lanzi C., Cassinelli G., Cuccuru G., Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1 Cellular and Molecular Life Sciences 2003 60 7 1449 1459
39. Mologni L., Sala E., Cazzaniga S., Inhibition of RET tyrosine kinase by SU5416 Journal of Molecular Endocrinology 2006 37 2 199 212
40. Carlomagno F., Vitagliano D., Guida T., The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes Cancer Research 2002 62 4 1077 1082
41. Carlomagno F., Vitagliano D., Guida T., Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl) -7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) Journal of Clinical Endocrinology and Metabolism 2003 88 4 1897 1902
42. Herbst R. S., Heymach J. V., O'Reilly M. S., Onn A., Ryan A. J., Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis Expert Opinion on Investigational Drugs 2007 16 2 239 249
43. Kim S., Yazici Y. D., Barber S. E., Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK787/ZK222584 and CPT-11 Head and Neck 2006 28 5 389 399 (Pubitemid 43673073)
44. Kim D. S., Franklyn J. A., Boelaert K., Eggo M. C., Watkinson J. C., McCabe C. J., Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibitor of DNA binding-3 autocrine pathway Journal of Clinical Endocrinology and Metabolism 2006 91 11 4603 4611
45. Strock C. J., Park J.-I., Rosen D. M., Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer Journal of Clinical Endocrinology and Metabolism 2006 91 1 79 84
46. Santoro M., Carlomagno F., Drug insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer Nature Clinical Practice Endocrinology and Metabolism 2006 2 1 42 52
47. Polverino A., Coxon A., Starnes C., AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts Cancer Research 2006 66 17 8715 8721
48. Carlomagno F., Anaganti S., Guida T., BAY 43-9006 inhibition of oncogenic RET mutants Journal of the National Cancer Institute 2006 98 5 326 334
49. Vidal M., Wells S., Ryan A., Cagan R., ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma Cancer Research 2005 65 9 3538 3541
50. Boughton D., Rosen L., Van Vugt A., Safety and antitumor activity of AMG 706 in patients with thyroid cancer: a subset analysis from a phase I dose-finding study Journal of Clinical Oncology 2006 24. abstract no. 3030, ASCO Meeting, Atlanta, Ga, USA
51. Kim S., Rosen L. S., Cohen E. E., A phase II study of axinitib (AG-013736), a potent inhibitor of VE GFRs, in patients with advanced thyroid cancer Journal of Clinical Oncology 2006 24. abstract no. 5529, ASCO Meeting, Atlanta, Ga, USA
52. Kloos R., Ringel M., Knopp M., Significant clinical and biological activity of RAF/VEGF-R kinase inhibitor BAY 43-9006 in patients with metastatic papillary thyroid carcinoma (PTC): updated results of a phase II study Journal of Clinical Oncology 2006 24. abstract no. 5534, ASCO Meeting, Atlanta, Ga, USA
53. Cohen E. E. W., Rosen L. S., Vokes E. E., Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study Journal of Clinical Oncology 2008 26 29 4708 4713
54. Sherman S. I., Wirth L. J., Droz J.-P., Motesanib diphosphate in progressive differentiated thyroid cancer The New England Journal of Medicine 2008 359 1 31 42
55. Gupta-Abramson V., Troxel A. B., Nellore A., Phase II trial of sorafenib in advanced thyroid cancer Journal of Clinical Oncology 2008 26 29 4714 4719
56. Kloos R. T., Ringel M. D., Knopp M. V., Phase II trial of sorafenib in metastatic thyroid cancer Journal of Clinical Oncology 2009 27 10 1675 1684
57. Schroyens W., Tueni E., Dodion P., Bodecker R., Stoessel F., Klastersky J., Validation of clinical predictive value of in vitro colorimetric chemosensitivity assay in head and neck cancer European Journal of Cancer 1990 26 7 834 838
58. Antonelli A., Fallahi P., Ferrari S. M., Dedifferentiated thyroid cancer: a therapeutic challenge Biomedicine and Pharmacotherapy 2008 62 8 559 563
59. Antonelli A., Ferrari S. M., Fallahi P., Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration European Journal of Endocrinology 2008 159 3 283 291
60. Antonelli A., Ferrari S. M., Fallahi P., Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests Clinical Endocrinology 2008 69 1 148 152